LINC 2023: Late-breaking Science Video Collection

Published: 20 June 2023

Views:
794
Likes:
7

Views:
794
Likes:
7
Share:

Now Playing
Part 1 | Session 9 of 9
LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
Sahil Parikh

Up Next

5m 2s

Part 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study Scott O Trerotola

5m 18s

Part 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups Marianne Brodmann

4m 51s

Part 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety Marianne Brodmann

4m 48s

Part 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date Matteo Tozzi

8m 14s

Part 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes Koen Deloose

7m 13s

Part 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease Yoshimitsu Soga

3m 49s

Part 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions Michel Bosiers

6m 6s

Part 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK Marc Sirvent

Average (ratings)

No ratings

Your rating

Overview

Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

Expert Interviews

Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.

9 sessions
AVPAS: Lutonix AV Post-Approval Study	Watch now
The ELEGANCE Registry: Ranger DCB In Under-Represented Groups	Watch now
RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety	Watch now
IN.PACT AV ACCESS: Outcomes to Date	Watch now
TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes	Watch now
POPCORN Registry: DCB Treatment for Peripheral Artery Disease	Watch now
MOTIV Bioresorbable Scaffold in BTK Lesions	Watch now
Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK	Watch now
LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions	Watch now

About the episode

LINC 23 - We are joined by Principal Investigator, Dr Sahil Parikh (Columbia University Irving Medical Center, US) to discuss Abbott's LIFE-BTK Randomised Controlled Trial.

The primary objective of the LIFE-BTK study was to assess the safety and effectiveness of the Esprit BTK everolimus-eluting system in treating narrowed infrapopliteal lesions in patients with critical limb ischemia. The full study design was released at LINC 23, where patients with peripheral artery disease specifically with below-the-knee arterial narrowing were randomized 2:1 to receive either treatment with the Esprit bioresorbable scaffold or balloon angioplasty.

Interview Questions:

What is the importance of this trial?
Please describe the Esprit BTK device and its unique features.
What were the study design and patient population?
What was the key focus of the trial?
What are the next steps?

Recorded remotely from New York, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent

Faculty Biographies

Sahil Parikh

Director of Endovascular Services and Assistant Professor of Medicine

Dr Sahil Parikh is Director of Endovascular Services and Assistant Professor of Medicine at Columbia University Vagelos College of Physicians & Surgeons in New York. His research interests include coronary artery disease, peripheral arterial disease including claudication, critical limb ischemia, renovascular disease, cerebrovascular disease, venous medicine and thrombosis.

Dr Parikh has authored over 50 original manuscripts and reviews, and frequently lectures at national meetings, including TCT, ACC and SCAI.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.